Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antidiabetic agents are insufficient.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control when combined with diet, exercise and other antidiabetic agents.

Linagliptin may be associated with a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Nasopharyngitis: inflammation of the upper airway passages. - Headache: mild to moderate head pain. - Upper respiratory tract infection: cough, sore throat or nasal congestion. - Dizziness: sensation of light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated pancreatic enzymes. - Severe hypersensitivity reactions: rash, angioedema or anaphylaxis. - Hepatic injury: marked elevation of liver enzymes. - Joint pain: acute arthralgia requiring medical attention. - Bullous skin disorders: rare blistering skin conditions.

When prescribing linagliptin, several safety considerations should be reviewed.

Renal impairment: monitor renal function as exposure may increase in severe impairment. Hepatic impairment: use with caution; liver function should be assessed. Hypersensitivity: discontinue immediately if rash, swelling or anaphylactic signs appear. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Elderly patients: observe for hypoglycaemia when combined with insulin or sulfonylureas. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Linagliptin can affect, or be affected by, other medicines.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: may increase risk of hypoglycaemia. - Rifampin: strong enzyme inducer that can reduce linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - ACE inhibitors or ARBs: observe renal function. - Warfarin: check INR periodically.